Trial Profile
Phase II, Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy of Olmutinib(Olita®) in Patients With NSCLC Who Harboring T790M Mutation Confirmed Using DNA Extracted From Extracellular Vesicles in Bronchoalveolar Lavage Fluid
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Olmutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Aug 2019 Status changed from active, no longer recruiting to completed.
- 01 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 27 Jul 2017 New trial record